United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Health Equity
Our Collaborations
Contact Us
Newsroom
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra™
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Provider
Patient
Pipeline & Data
Breast Radiation Score
Next Generation Cologuard
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Cancerguard™
Our Expertise
Cancerguard™ Science
Multi-Cancer Early Detection Thought Leadership
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Environmental, Social, and Governance (ESG)
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts in:
Company
December 09, 2020
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
November 02, 2020
Exact Sciences Mourns the Death of Dr. David Ahlquist, a Pioneer in Early Cancer Detection
October 28, 2020
Exact Sciences Commends Task Force for Draft Updated Guidelines that include Colorectal Cancer Screening Beginning at Age 45
October 12, 2020
Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer
June 16, 2020
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
May 29, 2020
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020
May 14, 2020
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
May 05, 2020
New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods
April 02, 2020
EXACT SCIENCES HIGHLIGHTS THE OPPORTUNITY TO SEEK SCREENING WITH COLOGUARD® THROUGH TELEHEALTH
March 11, 2020
FIGHT COLORECTAL CANCER RECEIVES GRANT FROM EXACT SCIENCES TO LAUNCH PROGRAM AIMED AT REDUCING PATIENT BARRIERS TO COLORECTAL CANCER SCREENING
December 05, 2019
Dr. David Ahlquist, Co-Inventor of Cologuard, Named a Fellow of the National Academy of Inventors
September 23, 2019
Cologuard® Gains FDA Approval for Use in Younger Americans, Ages 45 to 49
1
2
3
4